The outcomes of T cell activation and differentiation studies suggest that FOXM1 plays a crucial role in the modulation of tumor immune response and the utilization of FOXM1i could be a promising combinatorial approach to enhance the efficacy of immune-checkpoint blockers both in naïve and CR SCLC patients and help to shape the SCLC immune microenvironment towards enhanced antitumor immune response. This evidence concerns the gene FOXM1 and neoplasm.